We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: Endometrial Cancer
MedXY News
EnglishTag

Endometrial Cancer

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Impact of Mutated p53 on Type I Interferon Pathway Expression in Endometrial Cancer: Immune Modulatory Insights
newsI型インターフェロンimmune signaling

Impact of Mutated p53 on Type I Interferon Pathway Expression in Endometrial Cancer: Immune Modulatory Insights

By MedXY|Sep 12, 2026

This study reveals distinct alterations in the type I interferon pathway expression and signaling linked to mutated p53 subtypes in endometrial cancer, highlighting differing immune microenvironments that impact prognosis and therapeutic co

High Venous Thromboembolism Incidence in Endometrial Cancer Patients Undergoing Chemotherapy: Implications for Risk Stratification and Prophylaxis
newschemotherapy
venous thromboembolism

High Venous Thromboembolism Incidence in Endometrial Cancer Patients Undergoing Chemotherapy: Implications for Risk Stratification and Prophylaxis

By MedXY|Sep 1, 2026

Over 25% of endometrial cancer patients receiving chemotherapy develop venous thromboembolism, with advanced cancer stage as the key risk factor, highlighting the need for tailored risk assessment and preventive strategies.

Clinical Impact of Sentinel Lymph Node Biopsy in Atypical Endometrial Hyperplasia: Insights from a Multicenter Cohort Study
newsSentinel Lymph Node Biopsyatypical endometrial hyperplasia

Clinical Impact of Sentinel Lymph Node Biopsy in Atypical Endometrial Hyperplasia: Insights from a Multicenter Cohort Study

By MedXY|Aug 27, 2026

Sentinel lymph node biopsy in atypical endometrial hyperplasia patients identifies occult cancers and refines adjuvant treatment strategies, supporting its safe and feasible use for better risk stratification.

Trends in Incidence, Mortality, and Survival of Endometrial, Ovarian, and Cervical Cancers in Young Nordic Women: Insights from 40 Years of Registry Data
newsincidencesurvival

Trends in Incidence, Mortality, and Survival of Endometrial, Ovarian, and Cervical Cancers in Young Nordic Women: Insights from 40 Years of Registry Data

By MedXY|Aug 22, 2026

This article analyzes 40-year trends in incidence, mortality, and survival of endometrial, ovarian, and cervical cancers among Nordic women aged 0-49, highlighting evolving epidemiology and implications for age-specific prevention.

Metabolic and Bariatric Surgery in the Care of Endometrial Intraepithelial Neoplasia and Endometrial Cancer: Key Guidance from the SGO–SAGES Joint Statement
General Surgerybariatric surgeryEndometrial Cancer

Metabolic and Bariatric Surgery in the Care of Endometrial Intraepithelial Neoplasia and Endometrial Cancer: Key Guidance from the SGO–SAGES Joint Statement

By MedXY|Aug 12, 2026

A clear, evidence-based summary of the 2026 SGO–SAGES clinical practice statement recommending integration of metabolic and bariatric surgery into multidisciplinary care for women with EIN and endometrial cancer.

MLH1 Promoter Hypermethylation Does Not Impact Survival Outcomes in dMMR Endometrial Cancer Treated with Immune Checkpoint Inhibitors
newsimmune checkpoint inhibitorssurvival outcomes

MLH1 Promoter Hypermethylation Does Not Impact Survival Outcomes in dMMR Endometrial Cancer Treated with Immune Checkpoint Inhibitors

By MedXY|Aug 18, 2026

This study analyzes real-world data showing that MLH1 promoter hypermethylation and Lynch syndrome-associated genetic mutations confer similar response rates and survival outcomes in mismatch repair deficient endometrial cancer treated with

Adjunctive SGLT2 Inhibitors with Progestins Reduce Endometrial Cancer Risk in Benign Uterine Conditions: Insights from a Large Real-World Study
newsprogestin therapybenign uterine disease

Adjunctive SGLT2 Inhibitors with Progestins Reduce Endometrial Cancer Risk in Benign Uterine Conditions: Insights from a Large Real-World Study

By MedXY|Aug 18, 2026

A large retrospective study demonstrates that adding SGLT2 inhibitors to progestin therapy in women with benign uterine diseases reduces the risk of developing endometrial cancer and the need for hysterectomy.

Homologous Recombination Repair Gene Alterations Are Uncommon and Not Prognostic in Molecularly Classified Endometrial Cancer
newsPARP inhibitorshomologous recombination deficiency

Homologous Recombination Repair Gene Alterations Are Uncommon and Not Prognostic in Molecularly Classified Endometrial Cancer

By MedXY|Aug 18, 2026

In a 298-patient endometrial cancer cohort, HRR gene alterations were rare, enriched in aggressive tumor subsets, but did not predict survival or platinum sensitivity beyond integrated molecular classification.

Transcriptome Profiling With CCNA2 and E2F1 May Identify Platinum Insensitivity and Refine Prognosis in Endometrial Cancer
newstranscriptome profilingCCNA2 E2F1

Transcriptome Profiling With CCNA2 and E2F1 May Identify Platinum Insensitivity and Refine Prognosis in Endometrial Cancer

By MedXY|Aug 18, 2026

TCGA-based transcriptome analysis suggests high CCNA2 and E2F1 expression marks poor progression-free survival and probable platinum insensitivity in endometrial cancer, supporting pretreatment molecular stratification and alternative thera

Minimal Access vs. Open Hysterectomy in Endometrial Cancer: A Critical Synthesis of Surgical and Survival Outcomes
Clinical Updatesclinical outcomesEndometrial Cancer

Minimal Access vs. Open Hysterectomy in Endometrial Cancer: A Critical Synthesis of Surgical and Survival Outcomes

By MedXY|Jun 1, 2026

This review synthesizes findings from a large-scale cohort study comparing laparoscopic and abdominal hysterectomy, highlighting significant surgical advantages for laparoscopy despite complex survival data.

Selective vs. Universal NGS in Endometrial Cancer: A Cost-Efficiency Breakthrough
newscost-efficiencyEndometrial Cancer

Selective vs. Universal NGS in Endometrial Cancer: A Cost-Efficiency Breakthrough

By MedXY|Apr 24, 2026

A new study reveals that selective molecular profiling with MMR/p53 IHC followed by NGS for p53-abnormal tumors is more cost-efficient than universal NGS for advanced endometrial cancer, reducing unnecessary testing by 57%.

From 19 to 2: How a Simplified DNA Test Could Revolutionize Endometrial Cancer Detection
newsChảy máu tử cung bất thườngEndometrial Cancer

From 19 to 2: How a Simplified DNA Test Could Revolutionize Endometrial Cancer Detection

By MedXY|Apr 14, 2026

Researchers successfully reduced a 19-marker DNA panel to just 2 methylated DNA markers that detect endometrial cancer with 96% sensitivity and 82% specificity using self-collected vaginal fluid, offering a less invasive alternative to endo

Molecular Complexity of Endometrial Cancer: How Biomarker Patterns Vary Across Tumor Stages, Histology, and Molecular Subtypes
newsEndometrial Cancermolecular biomarkers

Molecular Complexity of Endometrial Cancer: How Biomarker Patterns Vary Across Tumor Stages, Histology, and Molecular Subtypes

By MedXY|Apr 9, 2026

A real-world study of 671 endometrial cancer patients reveals significant molecular heterogeneity. PTEN, ARID1A, and PIK3CA are the most prevalent biomarkers, while TP53 mutations and ERBB2 amplification cluster in advanced-stage and non-en

Immunotherapy Shows Consistent Efficacy in Recurrent Gynecologic Cancers Regardless of Prior Radiation Field Location
newscervical cancerEndometrial Cancer

Immunotherapy Shows Consistent Efficacy in Recurrent Gynecologic Cancers Regardless of Prior Radiation Field Location

By MedXY|Apr 6, 2026

This retrospective study challenges the assumption that prior radiation limits immunotherapy effectiveness in recurrent endometrial and cervical cancers, finding no significant difference in response rates or survival outcomes based on recu

Closing the Genomic Gap: Strategies to Enhance Biobanking Participation Among Black Women with Endometrial Cancer
Clinical UpdatesBiobankingEndometrial Cancer

Closing the Genomic Gap: Strategies to Enhance Biobanking Participation Among Black Women with Endometrial Cancer

By MedXY|Apr 2, 2026

This review analyzes community-validated strategies to improve biobanking engagement among Black women with endometrial cancer, highlighting return-of-value, transparency, and trust-building as essential components for reducing health dispa

Prioritizing Return of Value: A Roadmap to Enhancing Biobanking Participation Among Black Women with Endometrial Cancer
newsBiobankingCommunity-Engaged Research

Prioritizing Return of Value: A Roadmap to Enhancing Biobanking Participation Among Black Women with Endometrial Cancer

By MedXY|Mar 18, 2026

This community-engaged mixed-methods study identifies critical Return of Value (ROV) elements, such as genetic insights and community health benefits, to improve biobanking engagement among Black women with endometrial cancer, offering 14 a

Tamoxifen and Uterine Disease Risk in Young Breast Cancer Survivors: Evidence from a Target Trial Emulation Study
Clinical Updatesbreast cancerEndometrial Cancer

Tamoxifen and Uterine Disease Risk in Young Breast Cancer Survivors: Evidence from a Target Trial Emulation Study

By MedXY|Mar 13, 2026

A large-scale cohort study of premenopausal women demonstrates that adjuvant tamoxifen significantly increases the risk of endometrial cancer, hyperplasia, and polyps, with risk correlating to treatment duration.

Letrozole, Abemaciclib, and Metformin Triplet Therapy Shows Robust Activity in ER-Positive Endometrioid Endometrial Cancer
newsCDK4/6 inhibitorsclinical trials

Letrozole, Abemaciclib, and Metformin Triplet Therapy Shows Robust Activity in ER-Positive Endometrioid Endometrial Cancer

By MedXY|Feb 23, 2026

A phase 2 trial demonstrates that combining letrozole, abemaciclib, and metformin achieves a 32% response rate and 60% clinical benefit rate in ER+ endometrioid endometrial cancer, with notable efficacy in CTNNB1-mutated tumors and an inter

Beyond Breast Cancer: ESR1 Mutations Identified as Prevalent Primary Drivers in NSMP Low-Grade Endometrial Cancer
newsendocrine therapyEndometrial Cancer

Beyond Breast Cancer: ESR1 Mutations Identified as Prevalent Primary Drivers in NSMP Low-Grade Endometrial Cancer

By MedXY|Jan 13, 2026

Results from the UTOLA trial reveal that ESR1 mutations, a hallmark of AI resistance in breast cancer, are present in 22% of metastatic NSMP low-grade endometrial cancer patients before endocrine therapy, suggesting a need for molecular str

Molecular-Based Adjuvant Therapy Proves Safe and Effective in High-Intermediate Risk Endometrial Cancer: Results from the PORTEC-4a Trial
newsadjuvant therapyEndometrial Cancer

Molecular-Based Adjuvant Therapy Proves Safe and Effective in High-Intermediate Risk Endometrial Cancer: Results from the PORTEC-4a Trial

By MedXY|Jan 6, 2026

The PORTEC-4a trial confirms that molecular profiling safely guides adjuvant treatment in high-intermediate risk endometrial cancer, reducing overtreatment by 46% while maintaining non-inferiority in locoregional control compared to standar

1 / 2
12
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities